SORCE试验:中高危肾细胞癌术后辅助索拉非尼治疗结果
SORCE是一项国际随机双盲三臂III期试验,评估原发肾细胞癌手术切除后中高危复发风险患者使用索拉非尼的疗效。1,711例患者随机接受3年安慰剂、1年索拉非尼后2年安慰剂或3年索拉非尼治疗。结果显示3年索拉非尼与安慰剂相比在无病生存期或总生存期上无差异,索拉非尼不应作为肾细胞癌辅助治疗。
要点
- 中位无病生存期两组均未达到,限制性平均生存时间差异无统计学意义
- 索拉非尼组24%患者报告3级手足皮肤反应,超过半数12个月内停止治疗
核心结论
- 索拉非尼不应作为肾细胞癌的辅助治疗。
- 对于肾切除术后中高危复发风险患者,主动监测仍是标准治疗。
研究设计与样本
- SORCE是一项国际、随机、双盲、三臂III期组间试验。
- 共随机分配1,711例患者(A臂430例、B臂642例、C臂639例),按2:3:3比例分配。
- A臂为3年安慰剂,B臂为1年索拉非尼后2年安慰剂,C臂为3年索拉非尼。
- 索拉非尼初始剂量为400 mg每日两次口服,后修订为400 mg每日一次。
- 主要结局分析因外部结果修订为比较3年索拉非尼与安慰剂的研究者报告无病生存期。
主要发现
- 中位年龄58岁,71%为男性,84%为透明细胞组织学,53%为中危复发风险,47%为高危复发风险。
- 在所有随机分配患者、高危复发风险患者或仅透明细胞肾细胞癌患者中,无病生存期或总生存期均无差异。
- 尽管提供治疗调整,超过半数参与者在12个月内停止治疗;索拉非尼组24%参与者报告3级手足皮肤反应。
关键数值与推荐
- 索拉非尼组3级手足皮肤反应发生率为24%。
临床怎么用
- 肾切除术后中高危复发风险肾细胞癌患者不应接受辅助索拉非尼治疗。
- 主动监测应作为该患者群体的标准治疗。
- 当前国际辅助肾细胞癌试验RAMPART以主动监测为适当对照。
局限性
- 主要结局分析因外部结果而修订。
- 观察到非比例风险,限制了标准风险比解释。
- 尽管提供治疗调整,超过半数参与者在12个月内停止治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: SORCE is an international, randomized, double-blind, three-arm trial of sorafenib after surgical excision of primary renal cell carcinoma (RCC) found to be at intermediate or high risk of recurrence. PATIENTS AND METHODS: We randomly assigned participants (2:3:3) to 3 years of placebo (arm A), 1 year of sorafenib followed by 2 years of placebo (arm B), or 3 years of sorafenib (arm C). The initial sorafenib dose was 400 mg twice per day orally, amended to 400 mg daily. The primary outcome analysis, which was revised as a result of external results, was investigator-reported disease-free survival (DFS) comparing 3 years of sorafenib versus placebo. RESULTS: Between July 2007 and April 2013, we randomly assigned 1,711 participants (430, 642, and 639 participants in arms A, B, and C, respectively). Median age was 58 years, 71% of patients were men, 84% had clear cell histology, 53% were at intermediate risk of recurrence, and 47% were at high risk of recurrence. We observed no differences in DFS or overall survival in all randomly assigned patients, patients with high risk of recurrence, or patients with clear cell RCC only. Median DFS was not reached for 3 years of sorafenib or for placebo (hazard ratio, 1.01; 95% CI, 0.83 to 1.23; P = .95). We observed nonproportional hazards; the restricted mean survival time (RMST) was 6.81 years for 3 years of sorafenib and 6.82 years for placebo (RMST difference, 0.01 year; 95% CI, -0.49 to 0.48 year; P = .99). Despite offering treatment adaptations, more than half of participants stopped treatment by 12 months. Grade 3 hand-foot skin reaction was reported in 24% of participants on sorafenib. CONCLUSION: Sorafenib should not be used as adjuvant therapy for RCC. Active surveillance remains the standard of care for patients at intermediate or high risk of recurrence after nephrectomy and is the appropriate control of our current international adjuvant RCC trial, RAMPART.
引用
- Eisen T, Frangou E, Oza B, et al. Adjuvant Sorafenib for Renal Cell Carcinoma at Intermediate or High Risk of Relapse: Results From the SORCE Randomized Phase III Intergroup Trial. J Clin Oncol. 2020. PMID: 33052759. doi:10.1200/JCO.20.01800
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。